Literature DB >> 30037885

BCL-2 inhibition in AML: an unexpected bonus?

Marina Konopleva1, Anthony Letai2.   

Abstract

B-cell lymphoma 2 (BCL-2) was discovered at the breakpoint of the t(14;18) in follicular lymphoma >30 years ago. Although inhibition of BCL-2 first proved valuable in lymphoid malignancies, clinical progress in myeloid malignancies lagged. Here, we summarize the basic biology and preclinical results that spurred clinical BCL-2 inhibition in acute myeloid leukemia (AML). Response rates and toxicity for venetoclax in combination with standard AML agents, such as azacitidine, decitabine, and low-dose cytarabine, compare favorably with conventional induction chemotherapy. Durability of response requires further study.
© 2018 by The American Society of Hematology.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30037885      PMCID： PMC6235069          DOI： 10.1182/blood-2018-03-828269

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  47 in total

1.  Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.

Authors:  Marina Konopleva; Rooha Contractor; Twee Tsao; Ismael Samudio; Peter P Ruvolo; Shinichi Kitada; Xingming Deng; Dayong Zhai; Yue-Xi Shi; Thomas Sneed; Monique Verhaegen; Maria Soengas; Vivian R Ruvolo; Teresa McQueen; Wendy D Schober; Julie C Watt; Tilahun Jiffar; Xiaoyang Ling; Frank C Marini; David Harris; Martin Dietrich; Zeev Estrov; James McCubrey; W Stratford May; John C Reed; Michael Andreeff
Journal:  Cancer Cell       Date:  2006-11       Impact factor: 31.743

2.  Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics.

Authors:  Kristopher A Sarosiek; Cameron Fraser; Nathiya Muthalagu; Patrick D Bhola; Weiting Chang; Samuel K McBrayer; Adam Cantlon; Sudeshna Fisch; Gail Golomb-Mello; Jeremy A Ryan; Jing Deng; Brian Jian; Chris Corbett; Marti Goldenberg; Joseph R Madsen; Ronglih Liao; Dominic Walsh; John Sedivy; Daniel J Murphy; Daniel Ruben Carrasco; Shenandoah Robinson; Javid Moslehi; Anthony Letai
Journal:  Cancer Cell       Date:  2016-12-22       Impact factor: 31.743

3.  Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

Authors:  Matthew S Davids; Andrew W Roberts; John F Seymour; John M Pagel; Brad S Kahl; William G Wierda; Soham Puvvada; Thomas J Kipps; Mary Ann Anderson; Ahmed Hamed Salem; Martin Dunbar; Ming Zhu; Franklin Peale; Jeremy A Ross; Lori Gressick; Monali Desai; Su Young Kim; Maria Verdugo; Rod A Humerickhouse; Gary B Gordon; John F Gerecitano
Journal:  J Clin Oncol       Date:  2017-01-17       Impact factor: 44.544

4.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Authors:  Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore
Journal:  Nat Med       Date:  2013-01-06       Impact factor: 53.440

5.  The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.

Authors:  Mary Ann Anderson; Jing Deng; John F Seymour; Constantine Tam; Su Young Kim; Joshua Fein; Lijian Yu; Jennifer R Brown; David Westerman; Eric G Si; Ian J Majewski; David Segal; Sari L Heitner Enschede; David C S Huang; Matthew S Davids; Anthony Letai; Andrew W Roberts
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

Review 6.  Mitochondria-Judges and Executioners of Cell Death Sentences.

Authors:  Patrick D Bhola; Anthony Letai
Journal:  Mol Cell       Date:  2016-03-03       Impact factor: 17.970

7.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Authors:  Andrew W Roberts; Matthew S Davids; John M Pagel; Brad S Kahl; Soham D Puvvada; John F Gerecitano; Thomas J Kipps; Mary Ann Anderson; Jennifer R Brown; Lori Gressick; Shekman Wong; Martin Dunbar; Ming Zhu; Monali B Desai; Elisa Cerri; Sari Heitner Enschede; Rod A Humerickhouse; William G Wierda; John F Seymour
Journal:  N Engl J Med       Date:  2015-12-06       Impact factor: 91.245

8.  Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia.

Authors:  Guido Marcucci; John C Byrd; Guowei Dai; Marko I Klisovic; Peter J Kourlas; Donn C Young; Spero R Cataland; Diane B Fisher; David Lucas; Kenneth K Chan; Pierluigi Porcu; Zhong-Pin Lin; Sherif F Farag; Stanley R Frankel; James A Zwiebel; Eric H Kraut; Stanley P Balcerzak; Clara D Bloomfield; Michael R Grever; Michael A Caligiuri
Journal:  Blood       Date:  2002-08-22       Impact factor: 22.113

9.  BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells.

Authors:  Stephanie Beurlet; Nader Omidvar; Petra Gorombei; Patricia Krief; Carole Le Pogam; Niclas Setterblad; Pierre de la Grange; Christophe Leboeuf; Anne Janin; Maria-Elena Noguera; Florence Hervatin; Laure Sarda-Mantel; Marina Konopleva; Michael Andreeff; Andrea W Tu; Alice C Fan; Dean W Felsher; Anthony Whetton; Marika Pla; Robert West; Pierre Fenaux; Christine Chomienne; Rose Ann Padua
Journal:  Blood       Date:  2013-08-13       Impact factor: 22.113

10.  Genetic Biomarkers Of Sensitivity and Resistance to Venetoclax Monotherapy in Patients With Relapsed Acute Myeloid Leukemia.

Authors:  Brenda Chyla; Naval Daver; Kelly Doyle; Evelyn McKeegan; Xin Huang; Vivian Ruvolo; Zixing Wang; Ken Chen; Andrew Souers; Joel Leverson; Jalaja Potluri; Erwin Boghaert; Anahita Bhathena; Marina Konopleva; Relja Popovic
Journal:  Am J Hematol       Date:  2018-05-17       Impact factor: 10.047
View more
  41 in total

Review 1.  New Treatment Options for Acute Myeloid Leukemia in 2019.

Authors:  Marco Cerrano; Raphael Itzykson
Journal:  Curr Oncol Rep       Date:  2019-02-04       Impact factor: 5.075

Review 2.  Venetoclax-based therapies for acute myeloid leukemia.

Authors:  Veronica A Guerra; Courtney DiNardo; Marina Konopleva
Journal:  Best Pract Res Clin Haematol       Date:  2019-05-24       Impact factor: 3.020

3.  BET inhibitors reduce cell size and induce reversible cell cycle arrest in AML.

Authors:  Susu Zhang; Yue Zhao; Tiffany M Heaster; Melissa A Fischer; Kristy R Stengel; Xiaofan Zhou; Haley Ramsey; Ming-Ming Zhou; Michael R Savona; Melissa C Skala; Scott W Hiebert
Journal:  J Cell Biochem       Date:  2018-11-11       Impact factor: 4.429

4.  CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia.

Authors:  Johannes Schmoellerl; Inês Amorim Monteiro Barbosa; Thomas Eder; Tania Brandstoetter; Luisa Schmidt; Barbara Maurer; Selina Troester; Ha Thi Thanh Pham; Mohanty Sagarajit; Jessica Ebner; Gabriele Manhart; Ezgi Aslan; Stefan Terlecki-Zaniewicz; Christa Van der Veen; Gregor Hoermann; Nicolas Duployez; Arnaud Petit; Helene Lapillonne; Alexandre Puissant; Raphael Itzykson; Richard Moriggl; Michael Heuser; Roland Meisel; Peter Valent; Veronika Sexl; Johannes Zuber; Florian Grebien
Journal:  Blood       Date:  2020-07-23       Impact factor: 22.113

Review 5.  Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options.

Authors:  Daniel R Richardson; Steven D Green; Matthew C Foster; Joshua F Zeidner
Journal:  Curr Hematol Malig Rep       Date:  2021-02-20       Impact factor: 3.952

Review 6.  Acute Myeloid Leukemia: Update on Upfront Therapy in Elderly Patients.

Authors:  Gina Keiffer; Neil Palmisiano
Journal:  Curr Oncol Rep       Date:  2019-06-27       Impact factor: 5.075

7.  Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.

Authors:  Courtney D DiNardo; Keith Pratz; Vinod Pullarkat; Brian A Jonas; Martha Arellano; Pamela S Becker; Olga Frankfurt; Marina Konopleva; Andrew H Wei; Hagop M Kantarjian; Tu Xu; Wan-Jen Hong; Brenda Chyla; Jalaja Potluri; Daniel A Pollyea; Anthony Letai
Journal:  Blood       Date:  2018-10-25       Impact factor: 22.113

8.  Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia.

Authors:  Shruti Bhatt; Marissa S Pioso; Elyse Anne Olesinski; Binyam Yilma; Jeremy A Ryan; Thelma Mashaka; Buon Leutz; Sophia Adamia; Haoling Zhu; Yanan Kuang; Abhishek Mogili; Abner Louissaint; Stephan R Bohl; Annette S Kim; Anita K Mehta; Sneha Sanghavi; Youzhen Wang; Erick Morris; Ensar Halilovic; Cloud P Paweletz; David M Weinstock; Jacqueline S Garcia; Anthony Letai
Journal:  Cancer Cell       Date:  2020-11-19       Impact factor: 31.743

Review 9.  The role of autophagy in targeted therapy for acute myeloid leukemia.

Authors:  Wenxin Du; Aixiao Xu; Yunpeng Huang; Ji Cao; Hong Zhu; Bo Yang; Xuejing Shao; Qiaojun He; Meidan Ying
Journal:  Autophagy       Date:  2020-09-22       Impact factor: 16.016

Review 10.  Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis.

Authors:  Masayuki Yamashita; Paul V Dellorusso; Oakley C Olson; Emmanuelle Passegué
Journal:  Nat Rev Cancer       Date:  2020-05-15       Impact factor: 60.716
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.